Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com

Jon Faiz Kayyem, a director at Inhibrx Biosciences, Inc. (), purchased 5,000 shares of the company’s common stock on September 8, 2026. The total value of the transaction amounted to $567,580.

The shares were acquired at prices ranging from $113.30 to $113.55, with a weighted-average purchase price of $113.516 per share. The purchase comes as the stock trades at $114.34, down ~9% over the past week despite posting a remarkable 286% return over the last year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, with InvestingPro offering 13 additional exclusive tips for investors evaluating INBX.

Following this transaction, Kayyem’s indirect beneficial ownership in Inhibrx Biosciences includes 424,360 shares held by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust, 250,000 shares by the Jon Faiz Kayyem Revocable Trust, and another 250,000 shares by the Paige Gates-Kayyem Revocable Trust. Additionally, 69,843 shares are held in a custodial account for Child A, and another 69,843 shares are held in a custodial account for Child B, both managed by Kayyem.

In other recent news, Inhibrx Biosciences reported positive results from a Phase 2 trial of its drug INBRX-106, in combination with pembrolizumab, for head and neck cancer. The combination therapy showed a confirmed objective response rate of 48.3% compared to 26.5% for pembrolizumab alone. Additionally, the U.S. Food and Drug Administration accepted Inhibrx’s drug application for ozekibart, intended to treat unresectable or metastatic conventional chondrosarcoma, with a Prescription Drug User Fee Act goal date set for April 14, 2027. In financial developments, Inhibrx expanded its credit facility to $500 million with Oxford Finance LLC, securing $100 million immediately and the option to draw an additional $225 million at the lender’s discretion. Analyst firm Stifel reiterated its Buy rating on Inhibrx, maintaining a $325 price target and highlighting the potential of upcoming data disclosures. Meanwhile, Citizens reiterated a Market Perform rating on the company’s stock. These developments underscore significant progress in Inhibrx’s drug pipeline and financial strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.